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AbstrAct
Responding to increasing demands to demonstrate 
value-for-money (VfM) for maternal and newborn 
health interventions, and in the absence of VfM analysis 
in peer-reviewed literature, this paper reviews VfM 
components and methods, critiques their applicability, 
strengths and weakness and proposes how VfM 
assessments can be improved. VfM comprises four 
components: economy, efficiency, effectiveness and 
cost-effectiveness. Both ‘economy’ and ‘efficiency’ can 
be assessed with detailed cost analysis utilising costs 
obtained from programme accounting data or generic 
cost databases. Before-and-after studies, case–control 
studies or randomised controlled trials can be used to 
assess ‘effectiveness’. To assess ‘cost-effectiveness’, 
cost-effectiveness analysis (CEA), cost-utility analysis 
(CUA), cost-benefit analysis (CBA) or social return on 
investment (SROI) analysis are applicable. Generally, 
costs can be obtained from programme accounting data 
or existing generic cost databases. As such ‘economy’ 
and ‘efficiency’ are relatively easy to assess. However, 
‘effectiveness’ and ‘cost-effectiveness’ which require 
establishment of the counterfactual are more difficult to 
ascertain. Either a combination of CEA or CUA with tools 
for assessing other VfM components, or the independent 
use of CBA or SROI are alternative approaches proposed 
to strengthen VfM assessments. Cross-cutting themes 
such as equity, sustainability, scalability and cultural 
acceptability should also be assessed, as they provide 
critical contextual information for interpreting VfM 
assessments. To select an assessment approach, 
consideration should be given to the purpose, data 
availability, stakeholders requiring the findings and 
perspectives of programme beneficiaries. Implementers 
and researchers should work together to improve 
the quality of assessments. Standardisation around 
definitions, methodology and effectiveness measures to 
be assessed would help.
IntroductIon
There has been increasing demand by 
governments and international agen-
cies for implementers and researchers to 
demonstrate value-for-money (VfM) of 
global health interventions.1 2 Specifically, 
in maternal and newborn health (MNH), 
where the focus is on improving pregnancy 
experience and outcomes for mothers and 
their newborns throughout the continuum 
of care, calls for stronger accountability and 
performance monitoring to ensure VfM 
have been made by multiple stakeholders.3 
In low-income and middle-income coun-
tries (LMICs) where the burden of mortality 
and morbidity is highest, this call comes 
against the backdrop of increasing donor 
disbursements (US$2500 million based on 
a 2013 estimate) for MNH interventions 
Key questions
What is already known about this topic?
 ► In maternal and newborn health, there have been 
increasing calls by stakeholders and donors for 
value-for-money (VfM) assessments of what are 
often quite complex interventions.
 ► VfM has been variably defined. However, the 
consensus is that VfM is an approach which aims at 
better use of resources for the wider good of people.
 ► The components of VfM include economy, 
effectiveness, efficiency and cost-effectiveness.
What are the new findings?
 ► Alternative approaches to strengthen VfM 
assessments are proposed: combine either a cost-
effectiveness analysis or a cost-utility analysis with 
a detailed cost analysis and an effectiveness study 
or use either a cost-benefit analysis or social return 
on investment analysis independently.
 ► To provide critical contextual information to better 
understand and interpret VfM assessments, it is 
important to also assess and incorporate cross-
cutting themes such as equity, sustainability, 
scalability and cultural acceptability of the 
intervention.
How might this influence practice?
 ► Researchers and implementers need to work 
closely together to ensure VfM is robustly and 
comprehensively assessed.
 ► Systematic sharing of experiences and best practices 
between organisations is important to ensure that the 
best quality assessments are conducted. Agreement 
and standardisation around definitions, methodology 
and effectiveness measures to be assessed would 
help to improve quality of VfM assessments.
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Figure 1 Overseas development assistance (ODA) for maternal and newborn health, 2003–2013.
(figure 1).4 There is, however, still limited information 
regarding the best approach in assessing VfM.
This paper reviews the different VfM definitions that 
have been put forward and the components and methods 
used to assess each of them. The applicability, strengths 
and limitations of each method were critiqued in light 
of MNH interventions, and considerations required in 
choosing an approach for VfM assessments are high-
lighted.
What is value-for-money?
VfM generally refers to a product or service being worth 
the money spent on it. This concept of making good use 
of money is not novel and has been embedded in assess-
ments of several health interventions implemented in the 
public sector,1 2 where it is often used as a synonym for 
‘cost-effectiveness’.5 However, within the international 
development field, VfM generally refers to a broader 
concept encompassing economy, efficiency and effective-
ness, in addition to cost-effectiveness.5
The Organisation for Economic Co-operation and 
Development describes VfM as ‘the optimum combi-
nation of whole-life cost and quality to meet the user’s 
requirement’.5 New Zealand Aid describes VfM as 
‘achieving the best possible development outcomes 
over the life of an activity relative to the total cost of 
managing and resourcing that activity and ensuring 
that resources are used effectively, economically, and 
without waste’.6 The National Audit Office in the UK 
describes VfM as ‘the optimal use of resources to achieve 
the intended outcomes’.7 Finally, the UK Department 
for International Development describes VfM as ‘the 
best use of resources to achieve intended sustainable 
outcomes and impact’.8 These descriptions show that 
VfM consists of several interlinked components. Alto-
gether, the consensus is that VfM is not a tool or a 
method, but rather an approach to provide evidence for 
better resource allocation.5
To better describe VfM, the economy, effectiveness and 
efficiency (3Es) and cost-effectiveness (CE) framework 
was proposed. This framework is linked to a logical 
chain of events which reflects the intervention’s theory 
of change (figure 2).8 The VfM components address 
four key questions: Are implementers or funders buying 
the inputs of appropriate quality and at the right price? 
(economy), How well are implementers converting 
the inputs into outputs? (efficiency), How well are the 
outputs generated from an intervention achieving the 
desired outcomes? (effectiveness) and How much impact 
does an intervention achieve relative to the inputs that 
have been invested? (cost-effectiveness).8
How can VfM be assessed?
Several methods can be used to assess the components 
of the VfM framework. An aggregation of these methods 
provides insight into how VfM can be assessed. As no 
examples of a VfM analysis are found in peer-reviewed 
literature, a hypothetical case study (Mother and Baby 
Programme A) has been provided to illustrate the VfM 
assessment process (box 1).
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Figure 2 ‘Economy, effectiveness and efficiency (3Es) and cost-effectiveness (CE)’ framework for value-for-money.
Box 1 Maternal and newborn health value-for-money (VfM) hypothetical case study—‘Mother and baby Programme A’
Project title: Improving availability of emergency obstetric care (EmOC).
background: A grant was received from an international donor to reduce maternal mortality by increasing availability of EmOC in a designated 
district, which was known to have the least number of skilled providers per population and the highest maternal mortality ratio in the country. This 
was a 1-year long project. As part of the project mandate, the lead institution was required to embed VfM indicators in their management systems and 
conduct a VfM assessment of the intervention at the end of the project life cycle. Specifically, the intervention involved training midwives on context-
specific best practices for EmOC. Background data on number of skilled providers and pregnancy outcomes (newborn and maternal mortality) were 
collected at the start of the project (baseline).
Economy: Using an ingredient approach which reviewed all the various components purchased towards the project implementation; the total 
programme expenditure was US$100 000. The cost data were based on project accounting records. When data were not clear, more detail was 
gathered during interviews with finance managers. Cost of training included the component costs of training manuals, venue, equipment and travel 
for national and international facilitators. The most cost-intensive part of the expenditure was cost relating to travel of the international facilitators. 
However, the facilitators were working on a voluntary basis. No per diems were paid to trainees. Each 5-day training costs US$5000.
Efficiency: The target to train 400 midwives by the end of the project was met. These midwives were trained at a cost of $250 per trained midwife. 
Working together with the Ministry of Health helped to ensure that the appropriate staff were trained and efforts were not duplicated.
Effectiveness: Compared to baseline (year before the intervention), there were 50 fewer maternal deaths in the year following the trainings. When 
disaggregated, most significant reduction in maternal deaths occurred in subdistrict A where most of the maternal deaths in the district previously 
occurred. Similarly, there were 400 fewer stillbirths. The maternal case fatality rate was 0.6% compared to 1.5% at baseline.
cost-effectiveness: Cost-effectiveness analysis was used. A decision tree was used to compare costs and benefits at baseline and follow up. It cost 
US$2000 and US$250 to save each additional maternal life and prevent stillbirths, respectively.
overall VfM assessment: The training was conducted in the area with the greatest need and when compared to other similar capacity building 
interventions (referenced elsewhere), it yielded higher efficiency and effectiveness and was more cost-effective. The training was deemed culturally 
relevant and useful by the key stakeholders as it was designed to be context-specific for low-resource settings. Overall, the project was considered to 
have offered VfM although it was considered important to explore more sustainable implementation models beyond the lifetime of the project.
Economy and efficiency
Economy is not just about the cheapest option but also 
about purchasing high-quality inputs at the best price.8 
Economy is assessed using a detailed cost analysis9 and 
based on financial rather than economic costs. Finan-
cial costs are described as ‘explicit costs’ covering actual 
implementation costs which can be direct or indirect. A 
direct cost is a price that can be completely attributed to 
the production of a cost object (such as a project). Indi-
rect costs such as administration and overhead costs are 
not directly accountable to a cost object. Both direct and 
indirect costs may be either fixed or variable depending 
on whether they respond directly and proportionally to 
changes in volume purchased or sold. For example, in 
the case study, cost of training manuals is a direct cost 
(box 1). The unit cost for each manual may remain the 
same despite the number or manuals printed (fixed) 
or may change, for example, unit cost decreases as the 
quantity printed increases (variable). Economic costs, on 
the other hand, are viewed as more comprehensive, since 
in addition to the actual costs paid (financial costs) these 
also include ‘implicit costs,’ such as opportunity costs 
(the ‘cost of the alternative forgone’, eg, the cost of the 
time taken off work to attend a training).10 Furthermore, 
economic costs have to be annualised over the project 
lifetime at a discount rate, since the future value of money 
spent today is generally presumed to be greater than its 
present value.10 Both financial and economic costs have 
been used in MNH cost analyses.11 12 In the case study, 
financial costs were used (box 1). Although financial 
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costs are more relevant for VfM assessments, there is 
value in estimating economic costs, as these could form 
the basis for economic evaluations in which cost-effective-
ness of interventions are assessed.13
To generate the cost data needed for VfM assess-
ments, assessors have the choice of either the bottom-up 
(ingredient) or the top-down (expenditure) approach.14 
Unlike the top-down approach which breaks down total 
‘expenditure’ into component costs (CTotal=>C1+C2+C3), 
the bottom-up approach builds-up the ‘ingredients’ to 
estimate the total cost (C1 +C2+C3 =>CTotal), as utilised 
in the case study (box 1). Both health economists and 
MNH experts who have conducted costing exercises 
recommend the bottom-up approach, which utilises 
micro-costing methods in identifying and valuing each 
resource required for a specific intervention.10 13 15 This 
approach allows for analysts and policymakers to check 
and verify each individual component included in an 
analysis and make decisions on where to save money 
without compromising on quality.13 15
Cost data can be gathered from programme accounting 
data as in the case study (box 1) and by Saronga et al13 or it 
can be collected from existing generic cost databases.15 A 
commonly used cost database is the WHO-CHOICE data-
base developed by the WHO as the underlying framework 
for the CHOosing Interventions that are Cost-Effec-
tive (CHOICE) project.16 It is considered good practice 
to state the currency and year in which the cost data were 
collected. These costs can be subsequently converted to 
International Dollars (I$) using the purchasing power 
parity conversion factors, as was done by McPake et al.17 
Such a conversion allows for ease of comparison across 
similar interventions and models.18
Efficiency which can be viewed as productivity and 
builds on economy refers to the cost of inputs per output 
produced. Efficiency is generally estimated using simple 
arithmetic, dividing the total costs (economy) by the 
output generated. This requires assessing whether the 
costs of inputs per outputs is comparable with similar 
interventions, as was done by Trémolet et al.19 For 
example, some MNH studies reporting cost analyses of 
emergency obstetric care training conducted in LMICs, 
also estimated the costs/training/participant,11 20 which 
is an indicator of efficiency.19 (box 1) When the cost 
currency and year in which the study was conducted are 
stated, conversion to I$ can be done and comparisons can 
then be made to establish which intervention/strategy is 
more efficient.18
Both economy and efficiency are within the direct 
control of the programme implementers and funders 
since they make the decision on how the funds are allo-
cated and spent. As such they can make the choice(s) on 
how to achieve economy and efficiency. These choice(s) 
and the rationale that guided them are required to fully 
demonstrate these VfM components. Efforts should be 
focused on optimising economy and efficiency either by 
decreasing the inputs that produce a specified output or 
by increasing the outputs derived from the input.21
Additional consideration regarding the quality of the 
input(s) should be detailed in a supportive narrative for 
‘economy’.19 Such rigour should be part of the standard 
procurement process, which would allow assessors to 
evaluate if they have purchased inputs at best possible 
price, when quality, quantity and availability consider-
ations are made. For efficiency, meeting the project 
targets may be taken as a proxy-indicator, as such, project 
delays and reasons for not meeting the objectives can 
be highlighted.19 In the case study, existing government 
structures were used to achieve project targets (box 1).
Effectiveness and cost-effectiveness
Effectiveness and cost-effectiveness are intricately linked. 
Both are dependent of external factors which may not be 
controllable by the implementers.8 Effectiveness demon-
strates capacity of the intervention to deliver the intended 
outcome,21 while cost-effectiveness describes the amount 
of input required to deliver this outcome.8
Cost-effectiveness analysis (CEA), cost-utility anal-
ysis (CUA) and cost-benefit analysis (CBA) have been 
conventionally used to demonstrate ‘cost-effectiveness’. 
However, more recently and across different areas of 
global health, there has been growing interest in a new 
method, social return on investment (SROI).1 Most MNH 
cost-effectiveness studies have used CEA or CUA, while 
CBA and SROI are less frequently used22–26 (box 2). All 
four analytical tools provide some form of ‘cost-effective-
ness’ ratio as an output of analysis. Across these tools, the 
definition of ‘cost’ is essentially the same; however, the 
manner of accounting for effectiveness differs9 (table 1).
Examples of effectiveness measures that have been used 
in evaluating MNH interventions include but are not 
limited to: number of obstetric complications successfully 
managed, maternal lives saved, stillbirths prevented and 
newborn lives saved24 (box 2). These outcomes are gener-
ally expressed in ‘natural units’ that can be measured 
in principle, as is done in CEA. CEA has been relatively 
easy to apply, especially as effectiveness is accounted for 
in natural units, as in the hypothetical example (box 1) 
and the CEA example25 (box 2). This ease of application 
probably explains why it has been most frequently used 
in MNH. Researchers only need to report the exact count 
of the unit of interest. However, a CEA is unidimensional, 
as such it would be one of both effectiveness measures 
(‘number of years of mothers saved’ or ‘number of years 
of newborns saved’) but not both. This could limit the 
holistic evaluation of MNH interventions or require 
multiple assessments. Additionally, there is difficulty in 
comparing across disease conditions or different popu-
lation groups. Furthermore, CEA does not allow for 
capturing patient preferences and determination of 
whether or not an intervention is cost-effective based on 
a predetermined willingness-to-pay threshold.27
However, derived effectiveness measures such as 
disability-adjusted life years (DALYs) or quality-adjusted 
life years (QALYs), as is done with CUA, addresses some 
of these drawbacks. These measures combine morbidity 
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Box 2 summary of published examples of maternal and newborn health cost-effectiveness studies
cost-effectiveness analysis (Somigliana et al25)
background: Study assessed cost-effectiveness of a 24-hour ambulance service in Oyam district of northern Uganda.
costs data: Collected from the perspective of the district health provider. Direct costs included costs of the ambulance, fuel and drugs were included 
and indirect costs like personnel costs.
benefits data: Over a 3-month period, data were collected in a prospective fashion. Two experienced obstetricians managed all referred cases and 
made their assessments independently. Benefits were estimated based on number of years saved for mother and newborn (natural units), using the 
local life expectancy table as benchmark. Benefits of non-obstetrical referrals and those relating to quality of life and disability were excluded.
Analysis: Benefits to costs ratio estimated. Using WHO thresholds, the authors assessed cost-effectiveness of the intervention. Three per cent 
discount was applied. Sensitivity analysis was conducted.
results: Ninety-two obstetric referrals were recorded. Eleven (12%) were considered effective, corresponding to 611.7 years saved. Cost per year 
saved was US$15.82. The intervention remained extremely cost-effective with the sensitivity analysis, as the cost per year saved value remained 
lower than WHO US$30 benchmark for defining very attractive interventions.
cost-utility analysis (Broughton et al26)
background: Study assessed cost-effectiveness of an intervention that used a quality improvement strategy known as improvement collaborative to 
increase compliance of health workers with known standardised high impact interventions including emergency obstetric and newborn care in Niger.
costs data: Based on project accounting records. For costs not retrievable from this source, information was gathered during interviews with clinic 
managers and members of the quality improvement teams.
benefits data: Collected from participating facilities using a before and after design. Over a 5-month period (for baseline) and 3-month period (for 
follow up), 26 months apart. Benefits were facility-based maternal care outcomes. Postpartum haemorrhage and acute management of third stage 
labour indicators were recorded by reviewing partographs of spontaneous vaginal birth in participating sites each month. Emergency neonatal care 
was based on average compliance with immediate newborn care standards. Disability-adjusted life years (DALY) outcome measures were calculated 
using a 3% discount rate as well as disability weights for moderate and severe anaemia, 20.046 and 0.093, respectively. Age weighting was also 
used. Study did not take into account maternal health changes that may have occurred independently of the intervention.
Analysis: Calculations were based on the assumptions that average age of mother at delivery was 26 and average life expectancy was 54. A decision 
tree was used to compare costs and benefits at baseline and follow-up. Incremental cost-effectiveness ratio (ICER) was calculated.
results: Average delivery cost decreased from US$35 at baseline to US$28 at follow-up. The collaborative ICER was calculated as US$147/DALY 
averted.
cost-benefit analysis (Lappalainen et al 22)
background: Study reported a CBA that compared ‘no-screening’ and ‘screening’ alternatives for primary toxoplasmosis during pregnancy in Finland.
costs data: Collected from available Finnish sources that detailed cost of screening.
benefits data: Collected from existing sources. Monetised benefit data included direct (medical and institutional care) and indirect costs (value of loss 
of productivity—described as loss of earnings over presumed number of working years) for both newborn and mother. Intangible ‘benefits’ such as 
value of newborn death and psychosocial burden caused by false-positive or false-negative results were excluded.
Analysis: Assumptions were based on a Finnish prospective study, which showed that prevalence of toxoplasmosis seropositivity among pregnant 
mothers was 20.3%, incidence of 2.4/1000 seronegative pregnancies, fetomaternal transmission risk of 40% and treatment effectiveness of 50%. 
Four per cent discount rate was used. The calculations were carried out using a decision analysis.
results: Total financial value of benefit was divided by total costs of the intervention. Sensitivity analysis was conducted. Serological screening for 
congenital toxoplasmosis (US$30/pregnancy/year) was found to be cheaper than no screening (US$128/pregnancy/year). Net present value (NPV) of 
savings in Finland was reported at US$2.1 million annually.
social return on investment analysis (sroI) (Alberta Government23)
background: Study assessed the SROI of a programme that empowered pregnant homeless women by building their knowledge and skills, providing 
resources and support to live safer and healthier lives before, during and after pregnancy in Alberta, Canada.
costs data: Based on programme accounting data.
benefits data: Programme data and participant perceptions from interviews, secondary data from other sources such as Ontario 2010 data and Stats 
Canada report estimate (2002), adjusted to 2010. Benefits looked at 19 months of outcomes data. Based on insights from key stakeholders, project 
outcomes accounted for were improved maternal health outcomes, improved infant health outcomes, maintained custody of their infants, increased 
levels of empowerment, improved safety in their environment and personal relationships, positive influence in adopting safer sexual practices and 
improved housing situation of some clients. The values of all outcomes were presented as financial proxies from secondary data. Benefits were 
discounted for changes that would have happened without the intervention (dead weight), displacement (eg, how much of another positive activity did 
program displace)and attribution (what per cent of change was influenced by other factors). Evaluation data and findings from the literature helped 
determine these discounts. Drop-off rates used were based on estimates of project staff based on their experience. Total financial value of benefit was 
divided by total costs of the intervention. No sensitivity analysis was conducted.
Analysis: Total cost of the program was estimated at US$475 000 and NPV of financial value of benefits created by the intervention is estimated at 
US$3 438 469. The overall social return of the program was calculated to be US$8.24 for every US$1 invested.
and mortality in one metric9 26 (box 2). They take into 
account the value of the extra length of years gained and 
the quality of that extra life gained. QALYs are sometimes 
derived from the valuation of the populations, such as 
women who benefit from the intervention. For DALYs, 
health status is not based on self-report (as with QALYs), 
but on valuations provided by health experts.28 However, 
these experts have focused only on the five leading causes 
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of maternal mortality and their associated morbidities 
(haemorrhage, sepsis, eclampsia, obstructed labour and 
abortion). Other direct causes of maternal death such as 
ectopic pregnancy or indirect causes such as malaria and 
cardiac disease are not considered.28 Thus, DALYs are 
disease focused, while QALYs are health focused. QALYs 
are derived from scales tracking physical, mental and 
social dimensions of health.29 However, health encom-
passes more than these dimensions, particularly when 
viewed from an extra-welfarist perspective which takes 
account of broader outcomes.30 Indeed MNH interven-
tions usually have broader socioeconomic benefits, such 
as improved social capital or reduced stigma that need 
to be captured.31 Both QALYs and DALYs have limited 
applicability in estimating effectiveness and by extension 
VfM of life-saving interventions such as caesarean section, 
as both are based on health and disease, respectively.
In CBA and SROI, benefits which refer to ‘effective-
ness’ are monetised. Preferences of beneficiaries are 
taken into account in estimating the valuation of benefits 
for both, with SROI having the capacity to capture the 
opinions of a broad range of MNH stakeholders.32 33 CBA 
excludes ‘soft’ or ‘intangible’ outcomes such as psychoso-
cial burden and stigma.34 Excluding such outcomes from 
the ‘cost–benefit analysis’ limits the complete account of 
the programme benefits, even though they are benefits. 
SROI, on the other hand, accounts for these other bene-
fits, which are key components of MNH interventions, by 
using financial proxies. However, collecting these proxies 
may be challenging.33 Overall, both CBA and SROI are 
particularly sensitive to the assumptions made in their 
conduct, leaving a risk that both could be manipulated to 
generate desirable results. This highlights the importance 
of including sensitivity analyses and clearly documenting 
any assumptions that are made.33 35
To clearly demonstrate effectiveness and cost-effec-
tiveness, assessors need to demonstrate what would have 
occurred without the intervention. The process is known 
as establishing the counterfactual and can be done with 
before-and-after (quasi-experimental) studies, case–
control studies, step-wedge design studies or randomised 
controlled trials. The latter two methods are considered 
the most robust for evaluation of attribution. When 
primary effectiveness studies cannot be conducted, some 
MNH experts have used the Lives Saved Tool (LiST) to 
assess number of lives saved.36 LiST is a module within 
the demographic software package ‘Spectrum’ which 
captures national-level data on health status, mortality 
rates, coverage and effectiveness of over 60 MNH inter-
ventions.37 The database, ‘Global Value Exchange’ has 
been developed to standardise sensible financial proxies 
to account for outcomes for SROI (although this is still a 
work in progress).38
choosing a VfM approach for MnH interventions
There are several considerations required in choosing 
the methods for assessing VfM of an MNH intervention. 
First, clarity as to the purpose of the VfM assessment 
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and an understanding of the capabilities of the different 
methods are needed.
Data availability is also a critical consideration. All four 
approaches collect costs data from programme data or 
existing secondary data. Most challenges arise with the 
generation of effectiveness data to populate the cost-ef-
fectiveness component. Some MNH studies have used 
primary data26 while others have used available secondary 
data.22 23 Whichever option is used, transparency on how 
and where the data used was sourced is important.
Furthermore, consideration needs to be given to the 
capacity of the stakeholders that use VfM information to 
understand the findings of such analysis. Natural units 
of CEA are relatively easier to understand as compared 
with DALYs and QALYs of CUA, though CUA would 
be more relevant if ‘health’ or ‘disease’ states are the 
focus of interest. Similarly, monetised outcomes of CBA 
and SROI are easier to conceptualise for the lay public. 
However, both CBA and SROI have been described as 
time consuming and reliant on monetised outcome data 
which is seldom available.33 35
Another key consideration is how the perspectives 
of beneficiaries are captured. Clearly, perspectives of 
women are essential to include for evidence-based deci-
sion-making to choose MNH interventions that can have 
a high potential for success. According to the recent 
synthesis report of the United Nations General Assembly, 
the focus of the post-2015 agenda rests firmly on lever-
aging new evaluation measures of subjective well-being 
that can capture social progress, human well-being, secu-
rity, justice, equality and sustainability, from the ‘real 
beneficiaries’.39 SROI, though challenging, may prove 
an invaluable tool to meet this need, given its required 
engagement of stakeholders throughout the process, 
including their input as to what costs and benefits should 
be included for analysis, how long the benefits last for 
and what portion of the outcomes are attributable to the 
intervention. If, however, other methods are being used, 
then deliberate efforts to capture such perspectives are 
needed.
Making the VfM judgement
To conduct a comprehensive VfM assessment incor-
porating all components, one approach is to combine 
either a CEA or a CUA with a detailed cost analysis and an 
effectiveness study. The other approach is to use either 
a CBA or SROI independently. These two approaches 
would help to generate the quantitative basis for VfM 
assessments in MNH.
However, the emphasis of a VfM assessment is and 
should always be on achieving the optimal balance 
of the 3Es and CE.21 As such, after the estimations for 
each of these elements have been made, it is critical 
to make a judgement on the overall VfM of the inter-
vention. This ‘judgement’ requires an accompanying 
narrative providing contextual information explaining 
any additional considerations as well as justification for 
choices made. This narrative should incorporate equity 
considerations around the effectiveness of the interven-
tion,8 19 especially as widespread inequalities in MNH 
programme implementation have been reported.40 Such 
consideration is in line with the new sustainable devel-
opment goals.39 While some have argued that equity can 
be incorporated into VfM assessments as a dimension 
of the VfM component—effectiveness—others argue 
that it should be assessed as a stand-alone fourth ‘E’.41 
In the MNH area, disaggregated coverage indicators 
from representative surveys, comparing various segments 
of the benefitting population, have been used to assess 
equity (box 1).40
Cross-cutting themes such as sustainability, scalability 
and cultural acceptability should also be assessed and 
incorporated within the narrative (box 1). These are crit-
ical themes to consider, particularly for interventions that 
aim to improve maternal and newborn health which are 
often multicomponent, complex interventions involving 
a range of standards and actual practice.42 43 Qualitative 
engagements with key stakeholders would help provide 
these critical contextual information and insight for 
interpreting VfM assessments.5 44 For sustainability in 
particular, establishing the duration for which the impact 
of the intervention lasts either from evidence in the liter-
ature or expert opinion is essential. The duration can 
also be incorporated in the assessment of the cost-effec-
tiveness of VfM component.
conclusIon
VfM assessment is very much an evolving science. While 
the challenges limiting its development are not unique to 
the area of MNH, they are accentuated within the MNH 
area, due to the complexity of MNH interventions. To 
ensure the robustness of VfM assessments in the MNH 
area, synergy of researchers and practitioners is critical. 
These assessments would be greatly improved through 
systematic sharing of experiences and best practices 
among organisations. Capacity to demonstrate VfM will 
ensure that MNH interventions can remain competitive 
for the limited resources in the post-2015 era when more 
questions regarding VfM will likely continue to be asked.
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